ABEONA THERAPEUTICS INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ABEONA THERAPEUTICS INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00.
- ABEONA THERAPEUTICS INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $10.50M, a 199.60% increase year-over-year.
- ABEONA THERAPEUTICS INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $6.80M, a 5.30% increase year-over-year.
- ABEONA THERAPEUTICS INC. stock issued during period, value, new issues for fiscal 2025 was $17.30M, a 11.79% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. stock issued during period, value, new issues for fiscal 2024 was $15.47M, a 5.83% increase from fiscal 2023.
- ABEONA THERAPEUTICS INC. stock issued during period, value, new issues for fiscal 2023 was $14.62M, a 13.90% increase from fiscal 2022.
- ABEONA THERAPEUTICS INC. stock issued during period, value, new issues for fiscal 2022 was $12.84M, a 59.47% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $17.30M 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $22.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $10.50M 10-Q · filed 2026-08-13 | $22.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $6.80M 10-Q · filed 2026-05-13 | $15.82M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $15.47M 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $17.96M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $3.50M 10-Q · filed 2025-08-14 | $40.94M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $6.46M 10-Q · filed 2025-05-15 | $43.80M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $14.62M 10-K · filed 2025-03-20 |
| 2023-09-30 | $22.98M 10-Q · filed 2023-11-13 | $38.25M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-06-30 | $6.37M 10-Q · filed 2023-08-08 | $19.46M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-03-31 | $256.00K 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $8.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $12.84M 10-K · filed 2024-03-18 |
| 2022-09-30 | $4.19M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $8.05M 10-K · filed 2023-03-29 |
| 2021-09-30 | $33.00K 10-Q · filed 2022-11-14 | |
| 2019-06-30 | $12.62M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-11-09 | |
| 2017-12-31 | $86.17M 10-K · filed 2020-03-16 | |
| 2016-09-30 | $1.02M 10-Q · filed 2016-11-14 | |
| 2015-12-31 | $7.00M 10-K · filed 2016-03-30 | |
| 2015-06-30 | $7.00M 10-Q · filed 2015-11-16 | |
| 2014-12-31 | $12.31M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |